Literature DB >> 22146778

Alzheimer disease: Amyloid-targeting antibody performs well in phase II trial.

Katie Kingwell.   

Abstract

Entities:  

Year:  2011        PMID： 22146778     DOI： 10.1038/nrneurol.2011.183

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  1 in total

1.  Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.

Authors:  Susanne Ostrowitzki; Dennis Deptula; Lennart Thurfjell; Frederik Barkhof; Bernd Bohrmann; David J Brooks; William E Klunk; Elizabeth Ashford; Kisook Yoo; Zhi-Xin Xu; Hansruedi Loetscher; Luca Santarelli
Journal:  Arch Neurol       Date:  2011-10-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.